A randomized, double-blind, placebo-controlled pilot trial published in npj Parkinson’s Disease reported evidence supporting a sternum-worn vibrotactile device as a non-pharmacological adjunct for Parkinson’s disease. The study tests whether a wearable sensory input can influence clinical outcomes as compared with placebo. The report characterizes the trial as “compelling” for a pilot, emphasizing the role of adjunct interventions that may complement standard pharmacologic care. If subsequent studies confirm efficacy and define patient subgroups, device-based approaches could broaden treatment options. For the Parkinson’s pipeline, the publication reinforces ongoing interest in non-drug neuromodulation strategies that target symptoms or functional status with lower systemic risk.